Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PROBX
- Development stage
- Unknown
- Lead developer
- ADP Pharma Corporation
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PROBX is a probiotic food supplement developed and marketed by ADP Pharma Corporation in the Philippines. The product's active ingredient is *Bifidobacterium animalis* subsp. *lactis* BB-12®, a highly documented probiotic strain manufactured by CHR Hansen. It is formulated as a vanilla-flavored powder in sachets, with each sachet providing 6 billion colony-forming units (CFU). PROBX is indicated for the improvement of digestion, enhancement of natural resistance to intestinal infections, and general support of gastrointestinal and immune health. It is approved by the Philippine FDA as a food supplement and is marketed for use across all age groups, including infants, children, adults, and the elderly.
- Brand names
- PROBX
- Other names
- Bifidobacterium animalis subsp. lactis BB-12
Beyond the preview
Go deeper on PROBX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PROBX.